{
    "nct_id": "NCT06630247",
    "official_title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "Inclusion Criteria\n\n* For All Participants\n\n  * Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective.\n  * For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies.\n* Expansion Stage\n\n  * Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra).\n  * At least one measurable lesion as defined by RECIST, version 1.1.\n  * Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy.\n* At least one but no more than 3 prior lines of therapy.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo)\n\nExclusion Criteria\n\n* Prior anticancer treatment, including:\n\n  * Radiation therapy within 2 weeks before first dose of study treatment.\n* Known brain metastases or cranial epidural disease\n* Current or recent severe illness\n* Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria.\n* Active infection with hepatitis B virus or hepatitis C virus.\n* Malabsorption syndrome.\n* History of solid organ, autologous or allogenic stem cell transplant.\n* Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy.\n* Active autoimmune disease with skin involvement.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}